Journal Article (Letter)

DKFZ-2025-02017

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Sockel, K. ; Röllig, C. ; Mütherig, A. ; Crysandt, M. ; Zukunft, S. ; Herbst, R. ; Noppeney, R. ; Schäfer-Eckardt, K. ; Kaufmann, M. ; Oelschlaegel, U. ; Fiebig, F. ; Giagounides, A. ; Götze, K. ; Scholl, S. ; Lück, A. ; Rieger, K. ; Geer, T. ; Kiewe, P. ; Müller-Tidow, C. ; Serve, H.DKFZ* ; Baldus, C. D. ; Kaiser, U. ; Mahlmann, S. ; Schmidt, B. ; Parmentier, S. ; Illmer, T. ; Seggewiss-Bernhardt, R. ; Kiani, A. ; Linde, H. ; Dürk, H. ; Kramer, M. ; Kunadt, D. ; Schmidt-Brücken, K. ; Balaian, E. ; Trautmann-Grill, K. ; Ruhnke, L. ; Middeke, J. M. ; von Bonin, M. ; Ehninger, G. ; Thiede, C. ; Bornhäuser, M. ; Schetelig, J. ; Platzbecker, U.

2025
Wiley-Liss New York, NY

This record in other databases:  

Please use a persistent id in citations: doi:10.1002/ajh.70091

Abstract: Primary endpoint treatment-change-free survival (TCFS), defined as time from randomization to death or initiation of a new disease-modifying treatment in the phase 2 DELTA trial. AML, acute myeloid leukemia; EPAG, eltrombopag; HMA, hypomethylating agents; IC, intensive chemotherapy.

Keyword(s): DELTA ; elderly AML ; eltrombopag ; hypomethylating therapy ; thrombocytopenia

Note: 2025 Dec;100(12):2436-2441

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Frankfurt (FM01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2025

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---